• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by SenesTech Inc.

    8/6/24 4:02:05 PM ET
    $SNES
    Agricultural Chemicals
    Industrials
    Get the next $SNES alert in real time by email
    S-8 1 ea0209679-s8_senestech.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on August 6, 2024

    Registration No. 333-                 

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    SENESTECH, INC.
    (Exact name of registrant as specified in its charter)

     

    Delaware   20-2079805
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    23460 N. 19th Avenue, Suite 110
    Phoenix, Arizona 85027

    (Address of Principal Executive Offices) (Zip Code)

     

     

     

    SENESTECH, INC.

    2018 EQUITY INCENTIVE PLAN, AS AMENDED

    (Full Title of the Plan)

     

    Thomas C. Chesterman

    Executive Vice President, Chief Financial Officer, Treasurer and Secretary

    SenesTech, Inc.

    23460 N. 19th Avenue, Suite 110
    Phoenix, Arizona 85027
    (928) 779-4143

    (Name, Address, and Telephone Number, Including Area Code, of Agent for Service)

     

     

     

    Copy to:

    Brian H. Blaney, Esq.

    Katherine A. Beck, Esq.
    Stephanie T. Graffious, Esq.
    Greenberg Traurig, LLP
    2375 E. Camelback Road, Suite 800

    Phoenix, Arizona 85016

    (602) 445-8000

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Non-accelerated filer ☒   Smaller reporting company ☒
    Accelerated filer ☐       Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    We are filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register an aggregate of 200,000 additional shares (the “Additional Shares”) of our common stock, par value $0.001 per share (“Common Stock”), available for issuance under our 2018 Equity Incentive Plan, as amended (the “Plan”). The Additional Shares are being registered in addition to our Common Stock previously registered for issuance under the Plan pursuant to our Registration Statements on Form S-8 filed with the Commission on June 19, 2018 (Registration No. 333-225710), August 14, 2020 (Registration No. 333-246258), August 16, 2021 (Registration No. 333-258851), February 10, 2023 (Registration No. 333-269686), and September 26, 2023 (Registration No. 333-274700) (such prior registration statements on Form S-8, the “Prior Registration Statements”).

     

    This Registration Statement relates to securities of the same class as those registered under the Prior Registration Statements and is being filed in accordance with General Instruction E to Form S-8 regarding the registration of additional securities. Pursuant to such instruction, the contents of the Prior Registration Statement are hereby incorporated by reference and made part of this Registration Statement, except to the extent supplemented, superseded, or modified by the specific information set forth below or the specific exhibits attached hereto.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, which we have filed with the Commission, are incorporated by reference in this Registration Statement:

     

    (a)Annual Report on Form 10-K, as amended by the Form 10-K/A, for the year ended December 31, 2023, as filed with the Commission on February 21, 2024 and April 29, 2024, respectively;

     

    (b)Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, as filed with the Commission on May 9, 2024;

     

    (c)Definitive Proxy Statement on Schedule 14A, as filed with the Commission on May 28, 2024;

     

    (d)Current Reports on Form 8-K as filed with the Commission on February 27, 2024, May 1,2024, June 20, 2024, July 15, 2024, July 23, 2024, and August 5, 2024, but only to the extent that the items therein are specifically stated to be “filed” rather than “furnished” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”); and

     

    (e)The description of our Common Stock contained in the Registration Statement on Form 8-A (File No. 001-37941) as filed with the Commission on November 7, 2016, as updated by the description of our registered securities contained in Exhibit 4.1 to the Annual Report on Form 10-K/A for the year ended December 31, 2019, as filed with the Commission on April 21, 2020, including any amendment or report filed for the purpose of updating such description.

     

    In addition, all documents subsequently filed with the Commission by us pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents; except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under Item 2.02 or 7.01 of Form 8-K that is not deemed “filed” under such provisions. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. Under no circumstances will any information furnished under Item 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

     

    You should rely only on the information provided or incorporated by reference in this Registration Statement or any related prospectus. We have not authorized anyone to provide you with different information. You should not assume that the information in this Registration Statement or any related prospectus is accurate as of any date other than the date on the front of the document.

     

    II-1

     

     

    Item 8. Exhibits.

     

    Exhibit
    Number
      Description
         
    5.1+   Opinion of Greenberg Traurig, LLP
         
    10.1*   SenesTech, Inc. 2018 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K, filed with the Commission on July 15, 2024 (File no. 001-37941))
         
    23.1+   Consent of M&K CPAS, PLLC, independent registered public accounting firm
         
    23.2+   Consent of Greenberg Traurig, LLP (included in opinion filed as Exhibit 5.1)
         
    24.1+   Power of Attorney (included on signature page hereof)
         
    107+   Filing Fee Table

     

    +Filed herewith.

     

    *Incorporated by reference.

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Phoenix, state of Arizona, on August 6, 2024.

     

      SENESTECH, INC.
         
      By: /s/ Joel L. Fruendt
        Joel L. Fruendt
        President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Joel L. Fruendt and Thomas C. Chesterman, and each of them, as his or her true and lawful attorney-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Joel L. Fruendt   President, Chief Executive Officer and Director   August 6, 2024
    Joel L. Fruendt   (Principal Executive Officer)    
             
    /s/ Thomas C. Chesterman   Executive Vice President, Chief Financial Officer,    
    Thomas C. Chesterman   Treasurer and Secretary (Principal Financial and Accounting Officer)   August 6, 2024
             
    /s/ Jamie Bechtel   Chair of the Board   August 6, 2024
    Jamie Bechtel        
             
    /s/ Phil Grandinetti III   Director   August 6, 2024
    Phil Grandinetti III        
             
    /s/ Jake Leach   Director   August 6, 2024
    Jake Leach        
             
    /s/ Matthew K. Szot   Director   August 6, 2024
    Matthew K. Szot        

     

     

    II-3 

     

     

    Get the next $SNES alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNES

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SNES
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $15,480 worth of shares (8,569 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/6/26 5:40:20 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $94,524 worth of shares (48,138 units at $1.96) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/3/26 5:27:37 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    New insider Glenbrook Capital Management claimed ownership of 545,647 shares (SEC Form 3)

    3 - SenesTech, Inc. (0001680378) (Issuer)

    2/2/26 5:22:15 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    SEC Filings

    View All

    $SNES
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by SenesTech Inc.

    SCHEDULE 13G/A - SenesTech, Inc. (0001680378) (Subject)

    2/2/26 5:26:13 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SenesTech Inc. filed SEC Form 8-K: Leadership Update

    8-K/A - SenesTech, Inc. (0001680378) (Filer)

    1/28/26 5:26:33 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Inc. filed SEC Form 8-K: Leadership Update

    8-K - SenesTech, Inc. (0001680378) (Filer)

    1/28/26 4:01:46 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech's Evolve® Approved in New Zealand

    Supporting New Zealand's Predator Free 2050 Initiative Initial Stocking Order Fulfilled PHOENIX, Feb. 2, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, is pleased to announce that Evolve® has been approved for use in New Zealand by the Ministry for Primary Industries. SenesTech's exclusive distribution partner, Evicom, has been shipped its initial stocking order. Rodent overpopulation remains a major ecological and economic challenge in New Zealand, threatening native wildlife, agriculture, and urba

    2/2/26 8:00:00 AM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Expands International Reach with the Addition of the Belize Raptor Center as an Official Distributor of Evolve® Rat Birth Control

    SURPRISE, Ariz., Nov. 11, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the pioneer in fertility control for managing animal pest populations, proudly announces the addition of Sarah Mann and the Belize Raptor Center as the newest international distributor of Evolve® Rat Birth Control. Through the leadership of Sarah Mann with the support of the Pesticides Control Board of Belize, Evolve Rat received approval for import and distribution in Belize, a country whose biodiversity is being threatened by the alarming increase of unregulated rodenticides and the severe ecologic

    11/11/25 9:00:00 AM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $15,480 worth of shares (8,569 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/6/26 5:40:20 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $94,524 worth of shares (48,138 units at $1.96) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/3/26 5:27:37 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Financials

    Live finance-specific insights

    View All

    SenesTech Reports Third Quarter 2025 Financial Results with Record Revenue and Adjusted EBITDA

    77% Revenue Growth in Evolve® Rodent Birth Control™ Products Strong Cash Balance and Progress Toward Profitability SURPRISE, Ariz., Nov. 10, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Control™ products today announced its financial results for the third quarter ended September 30, 2025. Q3 2025 Financial Highlights Revenues increased by 43% to $690,000, a record for the Company, from $482,000 in Q3 2024.Evolve® Rodent Birth Control product sales

    11/10/25 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech to Report Third Quarter 2025 Financial Results on Monday, November 10, 2025

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern time PHOENIX, Nov. 3, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for pest management, will report third quarter 2025 financial results for the period ended September 30, 2025, after the market close on Monday, November 10, 2025. The Company has scheduled a conference call that same day, Monday, November 10, 2025, at 5:00 p.m. Eastern time, to review the results. Third Quarter 2025 Conference Call Details Date and Time: Monday, Novem

    11/3/25 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Reports Second Quarter 2025 Financial Results with Record Revenue and Record Gross Profit Margins

    94% Revenue Growth in Evolve™ Rodent Birth Control Products Strong Cash Balance and Sustained Progress Toward Profitability SURPRISE, Ariz., Aug. 7, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-registered rodent birth control products today announced its financial results for the second quarter ended June 30, 2025. Q2 2025 Highlights Revenues increased 36% to $625,000, a record for the Company, from $459,000 in Q2 2024.Evolve Rodent Birth Control products sales grew 94%

    8/7/25 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Leadership Updates

    Live Leadership Updates

    View All

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Names Nicole Williams as Chief Revenue Officer

    PHOENIX, Feb. 16, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today reported the appointment of Nicole Williams as Chief Revenue Officer. Ms. Williams was previously Chief Strategy Officer, and this appointment is part of an expansion and restructuring of the sales organization and commercialization efforts. The restructuring of the team comes after yet another quarter and fiscal ye

    2/16/23 9:00:00 AM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Announces Appointment of Vector and Pest Control Industry Veteran Joel Fruendt as Chief Executive Officer

    PHOENIX, Nov. 14, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced the appointment of Joel Fruendt as SenesTech's new Chief Executive Officer, succeeding Ken Siegel. Mr. Siegel, who is expected to retire at the end of the year, will remain as an Executive Director, in a consultative role, through the transition period. This leadership transition is part of SenesTech's ongoing strategic plan to drive the commercialization of ContraPest, its flagship product.

    11/14/22 9:10:00 AM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:12:23 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SEC Form SC 13G filed by SenesTech Inc.

    SC 13G - SenesTech, Inc. (0001680378) (Subject)

    11/12/24 4:30:48 PM ET
    $SNES
    Agricultural Chemicals
    Industrials